Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 8 de 8
1.
J Infect Dis ; 2024 May 14.
Article En | MEDLINE | ID: mdl-38743812

BACKGROUND: The cell envelope of Staphylococcus aureus contains two major secondary cell wall glycopolymers: capsular polysaccharide (CP) and wall teichoic acid (WTA). Both the CP and the WTA are attached to the cell wall and play distinct roles in S. aureus colonization, pathogenesis, and bacterial evasion of host immune defenses. OBJECTIVE: We aimed to investigate whether CP interferes with WTA-mediated properties. METHODS: Strains with natural heterogeneous expression of CP, strains with homogeneous high CP expression and CP-deficient strains were compared to WTA deficient controls regarding WTA dependent phage binding, cell adhesion, IgG deposition, and virulence in vivo. RESULTS: WTA-mediated phage adsorption, specific antibody deposition and cell adhesion were negatively correlated with CP expression. WTA, but not CP, enhanced the bacterial burden in a mouse abscess model, while CP overexpression resulted in intermediate virulence in vivo. CONCLUSIONS: CP protects the bacteria from WTA-dependent opsonization and phage binding. This protection comes at the cost of diminished adhesion to host cells. The highly complex regulation and mostly heterogeneous expression of CP has probably evolved to ensure the survival and optimal physiological adaptation of the bacterial population as a whole.

2.
ACS Infect Dis ; 9(11): 2133-2140, 2023 11 10.
Article En | MEDLINE | ID: mdl-37910786

The success of Staphylococcus aureus as a major cause for endovascular infections depends on effective interactions with blood-vessel walls. We have previously shown that S. aureus uses its wall teichoic acid (WTA), a surface glycopolymer, to attach to endothelial cells. However, the endothelial WTA receptor remained unknown. We show here that the endothelial oxidized low-density lipoprotein receptor 1 (LOX-1) interacts with S. aureus WTA and permits effective binding of S. aureus to human endothelial cells. Purified LOX-1 bound to isolated S. aureus WTA. Ectopic LOX-1 expression led to increased binding of S. aureus wild type but not of a WTA-deficient mutant to a cell line, and LOX-1 blockage prevented S. aureus binding to endothelial cells. Moreover, WTA and LOX-1 expression levels correlated with the efficacy of the S. aureus-endothelial interaction. Thus, LOX-1 is an endothelial ligand for S. aureus, whose blockage may help to prevent or treat severe endovascular infections.


Staphylococcal Infections , Staphylococcus aureus , Humans , Staphylococcus aureus/genetics , Staphylococcus aureus/metabolism , Endothelial Cells , Teichoic Acids/metabolism , Receptors, Scavenger/metabolism , Scavenger Receptors, Class E/genetics , Scavenger Receptors, Class E/metabolism
3.
Cell Rep ; 42(9): 113154, 2023 09 26.
Article En | MEDLINE | ID: mdl-37725513

Bacteria use quorum sensing (QS) to coordinate group behavior in response to cell density, and some bacterial viruses (phages) also respond to QS. In Staphylococcus aureus, the agr-encoded QS system relies on accumulation of auto-inducing cyclic peptides (AIPs). Other staphylococci also produce AIPs of which many inhibit S. aureus agr. We show that agr induction reduces expression of tarM, encoding a glycosyltransferase responsible for α-N-acetylglucosamine modification of the major S. aureus phage receptor, the wall teichoic acids. This allows lytic phage Stab20 and related phages to infect and kill S. aureus. However, in mixed communities, producers of inhibitory AIPs like S. haemolyticus, S. caprae, and S. pseudintermedius inhibit S. aureus agr, thereby impeding phage infection. Our results demonstrate that cross-species interactions dramatically impact phage susceptibility. These interactions likely influence microbial ecology and impact the efficacy of phages in medical and biotechnological applications such as phage therapy.


Bacteriophages , Staphylococcal Infections , Humans , Staphylococcus aureus/metabolism , Bacteriophages/metabolism , Staphylococcus/metabolism , Glycosyltransferases/metabolism , Bacterial Proteins/metabolism , Quorum Sensing
4.
Viruses ; 14(11)2022 11 08.
Article En | MEDLINE | ID: mdl-36366569

Staphylococcus aureus asymptomatically colonizes the nasal cavity of mammals, but it is also a leading cause of life-threatening infections. Most human nasal isolates carry Sa3 phages, which integrate into the bacterial hlb gene encoding a sphingomyelinase. The virulence factor-encoding genes carried by the Sa3-phages are highly human-specific, and most animal strains are Sa3 negative. Thus, both insertion and excision of the prophage could potentially confer a fitness advantage to S. aureus. Here, we analyzed the phage life cycle of two Sa3 phages, Φ13 and ΦN315, in different phage-cured S. aureus strains. Based on phage transfer experiments, strains could be classified into low (8325-4, SH1000, and USA300c) and high (MW2c and Newman-c) transfer strains. High-transfer strains promoted the replication of phages, whereas phage adsorption, integration, excision, or recA transcription was not significantly different between strains. RNASeq analyses of replication-deficient lysogens revealed no strain-specific differences in the CI/Mor regulatory switch. However, lytic genes were significantly upregulated in the high transfer strain MW2c Φ13 compared to strain 8325-4 Φ13. By transcriptional start site prediction, new promoter regions within the lytic modules were identified, which are likely targeted by specific host factors. Such host-phage interaction probably accounts for the strain-specific differences in phage replication and transfer frequency. Thus, the genetic makeup of the host strains may determine the rate of phage mobilization, a feature that might impact the speed at which certain strains can achieve host adaptation.


Bacterial Toxins , Staphylococcal Infections , Animals , Humans , Staphylococcus aureus , Staphylococcus Phages/genetics , Staphylococcus Phages/metabolism , Bacterial Toxins/genetics , Bacterial Toxins/metabolism , Staphylococcal Infections/microbiology , Life Cycle Stages , Mammals
5.
Nat Microbiol ; 6(6): 757-768, 2021 06.
Article En | MEDLINE | ID: mdl-34031577

Most clonal lineages of Staphylococcus epidermidis are commensals present on human skin and in the nose. However, some globally spreading healthcare-associated and methicillin-resistant S. epidermidis (HA-MRSE) clones are major causes of difficult-to-treat implant or bloodstream infections. The molecular determinants that alter the lifestyle of S. epidermidis have remained elusive, and their identification might provide therapeutic targets. We reasoned that changes in surface-exposed wall teichoic acid (WTA) polymers of S. epidermidis, which potentially shape host interactions, may be linked to differences between colonization and infection abilities of different clones. We used a combined epidemiological and functional approach to show that while commensal clones express poly-glycerolphosphate WTA, S. epidermidis multilocus sequence type 23, which emerged in the past 15 years and is one of the main infection-causing HA-MRSE clones, contains an accessory genetic element, tarIJLM, that leads to the production of a second, Staphylococcus aureus-type WTA (poly-ribitolphosphate (RboP)). Production of RboP-WTA by S. epidermidis impaired in vivo colonization but augmented endothelial attachment and host mortality in a mouse sepsis model. tarIJLM was absent from commensal human sequence types but was found in several other HA-MRSE clones. Moreover, RboP-WTA enabled S. epidermidis to exchange DNA with S. aureus via siphovirus bacteriophages, thereby creating a possible route for the inter-species exchange of methicillin resistance, virulence and colonization factors. We conclude that tarIJLM alters the lifestyle of S. epidermidis from commensal to pathogenic and propose that RboP-WTA might be a robust target for preventive and therapeutic interventions against MRSE infections.


Cell Wall/metabolism , Staphylococcal Infections/microbiology , Staphylococcus aureus/physiology , Staphylococcus epidermidis/physiology , Teichoic Acids/metabolism , Animals , Cell Wall/genetics , Female , Humans , Mice , Mice, Inbred BALB C , Staphylococcus aureus/genetics , Staphylococcus epidermidis/genetics
6.
Neuroscience ; 366: 149-161, 2017 Dec 16.
Article En | MEDLINE | ID: mdl-29037596

Neurons of the Grueneberg ganglion (GG) in the anterior nasal region of mice respond to a small set of odorous compounds, including given dimethylpyrazines present in mouse urine. Consequently, mouse pups living in murine colonies are presumably commonly exposed to such GG-activating substances. Since stimulation of the GG elicits alarm and stress reactions in mice, the question arises whether such a GG activation potentially inducing stress could be reduced when pups might rather feel secure in the presence of their mother. Being together with their warmth-giving dam, mouse pups experience a nest temperature of ∼35 °C. Therefore, we hypothesized that such a warm temperature may attenuate the responses of GG neurons to dimethylpyrazines. Monitoring the expression of the activity marker c-Fos, GG responses to dimethylpyrazines were significantly lower in pups exposed to these substances at 35 °C compared to exposure at 30 °C. By contrast, dimethylpyrazine-induced responses of neurons in the main olfactory epithelium were not diminished at 35 °C in comparison to 30 °C. The attenuated chemosensory responses of GG neurons at 35 °C coincided with a reduced dimethylpyrazine-evoked activation of the glomeruli in the olfactory bulb innervated by GG neurons. The reduction in dimethylpyrazine-evoked GG responses by warm temperatures was positively correlated with exposure time, suggesting that warm temperatures might enhance desensitization processes in GG neurons. In summary, the findings indicate that warm temperatures similar to those in mouse nests in the presence of the dam attenuate GG activation by colony-derived odorants.


Olfactory Bulb/metabolism , Olfactory Mucosa/metabolism , Pyrazines/administration & dosage , Sensory Receptor Cells/metabolism , Animals , Ganglia, Sensory/drug effects , Ganglia, Sensory/metabolism , Hot Temperature , Mice, Inbred C57BL , Odorants , Olfactory Bulb/drug effects , Olfactory Mucosa/drug effects , Proto-Oncogene Proteins c-fos/metabolism , Sensory Receptor Cells/drug effects
7.
Blood ; 111(4): 2364-73, 2008 Feb 15.
Article En | MEDLINE | ID: mdl-18083845

Bortezomib reversibly inhibits 26S proteasomal degradation, interferes with NF-kappaB, and exhibits antitumor activity in human malignancies. Zinc finger protein Sp1 transactivates DNMT1 gene in mice and is functionally regulated through protein abundance, posttranslational modifications (ie, ubiquitination), or interaction with other transcription factors (ie, NF-kappaB). We hypothesize that inhibition of proteasomal degradation and Sp1/NF-kappaB-mediated transactivation may impair aberrant DNA methyltransferase activity. We show here that, in addition to inducing accumulation of polyubiquitinated proteins and abolishment of NF-kappaB activities, bortezomib decreases Sp1 protein levels, disrupts the physical interaction of Sp1/NF-kappaB, and prevents binding of the Sp1/NF-kappaB complex to the DNMT1 gene promoter. Abrogation of Sp1/NF-kappaB complex by bortezomib causes transcriptional repression of DNMT1 gene and down-regulation of DNMT1 protein, which in turn induces global DNA hypomethylation in vitro and in vivo and re-expression of epigenetically silenced genes in human cancer cells. The involvement of Sp1/NF-kappaB in DNMT1 regulation is further demonstrated by the observation that Sp1 knockdown using mithramycin A or shRNA decreases DNMT1 protein levels, which instead are increased by Sp1 or NF-kappaB overexpression. Our results unveil the Sp1/NF-kappaB pathway as a modulator of DNA methyltransferase activity in human cancer and identify bortezomib as a novel epigenetic-targeting drug.


Antineoplastic Agents/pharmacology , Boronic Acids/pharmacology , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation/drug effects , Gene Silencing/drug effects , Leukemia, Myeloid, Acute/genetics , NF-kappa B/physiology , Pyrazines/pharmacology , Transcription, Genetic/drug effects , Bortezomib , DNA (Cytosine-5-)-Methyltransferases/drug effects , Humans , Protein Kinases/drug effects , Protein Kinases/genetics , Protein Kinases/metabolism
8.
Eur J Immunol ; 37(9): 2549-61, 2007 Sep.
Article En | MEDLINE | ID: mdl-17705132

Murine T-bet (T-box expressed in T cells) is a master regulator of IFN-gamma gene expression in NK and T cells. T-bet also plays a critical role in autoimmunity, asthma and other diseases. However, cis elements or trans factors responsible for regulating T-bet expression remain largely unknown. Here, we report on our discovery of six Sp1-binding sites within the proximal human T-BET promoter that are highly conserved among mammalian species. Electrophoretic mobility shift assays demonstrate a physical association between Sp1 and the proximal T-BET promoter with a direct dose response between Sp1 expression and T-BET promoter activity. Ectopic overexpression of Sp1 also enhanced T-BET expression and cytokine-induced IFN-gamma secretion in NK cells and T cells. Mithramycin A, which blocks the binding of Sp1 to the T-BET promoter, diminished both T-BET expression and IFN-gamma protein production in monokine-stimulated primary human NK cells. Collectively, our results suggest that Sp1 is a positive transcriptional regulator of T-BET. As T-BET and IFN-gamma are critically important in inflammation, infection, and cancer, targeting Sp1, possibly with mithramycin A, may be useful for preventing and/or treating diseases associated with aberrant T-BET or IFN-gamma expression.


Gene Expression Regulation , Sp1 Transcription Factor/metabolism , T-Box Domain Proteins/metabolism , Transcription, Genetic/genetics , Animals , Base Sequence , Cell Line , Conserved Sequence , Humans , Interferon-gamma/genetics , Interferon-gamma/metabolism , Killer Cells, Natural/drug effects , Killer Cells, Natural/metabolism , Molecular Sequence Data , Plicamycin/analogs & derivatives , Plicamycin/pharmacology , Promoter Regions, Genetic/genetics , Sequence Alignment , T-Box Domain Proteins/genetics
...